PMID- 31701722
OWN - NLM
STAT- MEDLINE
DCOM- 20191118
LR  - 20200108
IS  - 1000-6834 (Print)
IS  - 1000-6834 (Linking)
VI  - 35
IP  - 4
DP  - 2019 Jul 28
TI  - [Effects of puerarin on rats with type 2 diabetes mellitus].
PG  - 355-358
LID - 10.12047/j.cjap.5786.2019.075 [doi]
AB  - OBJECTIVE: To investigate the therapeutic effects of puerarin on rats with type 2 
      diabetes mellitus (T2DM). METHODS: T2DM models were established by high fat and 
      high glucose feeding combined with a one-time intraperitoneal injection of 
      streptozotocin (STZ, 60 mg/kg). Then the rats were randomly divided into normal 
      group, model group, metformin group (MET, 40 mg/kg), puerarin low-dose group, 
      medium-dose group and high-dose group (40, 80, 160 mg/kg), n=10. After the model 
      was successfully established, rats were treated with corresponding drug 
      intervention by intragastrical administration for 4 weeks. The body weight and 
      fasting blood glucose (FBG) were measured per week, and blood samples were 
      collected 24 h after the last administration, and serum levels of blood glucose, 
      serum triglyceride (TG), total cholesterol (TC), low-density 
      lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholestrol (HDL-C), 
      serum enzyme activities of aspartate aminotransferase (AST), alanine 
      aminotransferase (ALT), blood urea nitrogen (BUN), serum creatinine (SCr), and 
      blood uric acid (UA) were measured. RESULTS: As compared with normal group, the 
      body weight was decreased after 4 weeks-intervention in the model group, and the 
      levels of FBG, TC, TG, LDL-C, ALT, AST, BUN, SCr and UA were all increased,while 
      HDL-C level was decreased (P＜0.05). As compared with model group,the body weight 
      was increased after 4 weeks-intervention in metformin group and puerarin groups, 
      and the levels of FBG, TC, TG, LDL-C, ALT, AST, BUN, SCr and UA were decreased 
      (P＜0.01); meanwhile, HDL-C level was increased significantly (P＜0.05). 
      CONCLUSION: Puerarin can reduce the weight loss of T2DM rats, decrease the blood 
      lipid and blood glucose levels of T2DM rats, which can be used to control T2DM.
FAU - Yang, Fei
AU  - Yang F
AD  - Department of Endocrinology, Characteristic Medical Center of the Chinese 
      People's Armed Police Force, Tianjin 300162.
FAU - Dong, Xin-Xin
AU  - Dong XX
AD  - Department of Surgical Oncology, Characteristic Medical Center of the Chinese 
      People's Armed Police Force, Tianjin 300162, China.
FAU - Guo, Yun
AU  - Guo Y
AD  - Department of Endocrinology, Characteristic Medical Center of the Chinese 
      People's Armed Police Force, Tianjin 300162.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Ying Yong Sheng Li Xue Za Zhi
JT  - Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = 
      Chinese journal of applied physiology
JID - 9426407
RN  - 0 (Blood Glucose)
RN  - 0 (Isoflavones)
RN  - 0 (Lipids)
RN  - 5W494URQ81 (Streptozocin)
RN  - Z9W8997416 (puerarin)
SB  - IM
MH  - Animals
MH  - Blood Glucose
MH  - Diabetes Mellitus, Experimental/*drug therapy
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Isoflavones/*pharmacology
MH  - Lipids/blood
MH  - Random Allocation
MH  - Rats
MH  - Streptozocin
MH  - Weight Loss
EDAT- 2019/11/09 06:00
MHDA- 2019/11/19 06:00
CRDT- 2019/11/09 06:00
PHST- 2019/11/09 06:00 [entrez]
PHST- 2019/11/09 06:00 [pubmed]
PHST- 2019/11/19 06:00 [medline]
AID - 10.12047/j.cjap.5786.2019.075 [doi]
PST - ppublish
SO  - Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2019 Jul 28;35(4):355-358. doi: 
      10.12047/j.cjap.5786.2019.075.